GALECTIN THERAPEUTICS INC. Cash and Cash Equivalents
GALECTIN THERAPEUTICS INC. (GALT) had Cash and Cash Equivalents of $13.27 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash and Cash Equivalent
us-gaap:CashAndCashEquivalentsAtCarryingValue · last filed 2026-08-14
- 2026-06-30: Cash and Cash Equivalents, at Carrying Value $13.27M.
- 2026-03-31: Cash and Cash Equivalents, at Carrying Value $14.11M.
- 2025-12-31: Cash and Cash Equivalents, at Carrying Value $17.72M.
- 2025-09-30: Cash and Cash Equivalents, at Carrying Value $11.53M.
| Period end | Cash and Cash Equivalents, at Carrying Value |
|---|---|
| 2026-06-30 | $13.27M 10-Q · filed 2026-08-14 |
| 2026-03-31 | $14.11M 10-Q · filed 2026-05-15 |
| 2025-12-31 | $17.72M 10-Q · filed 2026-08-14 |
| 2025-09-30 | $11.53M 10-Q · filed 2025-11-14 |
| 2025-06-30 | $13.77M 10-Q · filed 2025-08-14 |
| 2025-03-31 | $7.43M 10-Q · filed 2025-05-15 |
| 2024-12-31 | $15.12M 10-K · filed 2026-03-31 |
| 2024-09-30 | $27.06M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $25.60M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $23.55M 10-Q · filed 2024-05-15 |
| 2023-12-31 | $25.66M 10-K · filed 2025-03-31 |
| 2023-09-30 | $20.36M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $17.97M 10-Q · filed 2023-08-14 |
| 2023-03-31 | $17.80M 10-Q · filed 2023-05-15 |
| 2022-12-31 | $18.59M 10-K · filed 2024-03-29 |
| 2022-09-30 | $15.83M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $24.18M 10-Q · filed 2022-08-15 |
| 2022-03-31 | $31.61M 10-Q · filed 2022-05-16 |
| 2021-12-31 | $39.65M 10-K · filed 2023-03-30 |
| 2021-09-30 | $36.60M 10-Q · filed 2021-11-15 |
| 2021-06-30 | $31.60M 10-Q · filed 2021-08-16 |
| 2021-03-31 | $20.76M 10-Q · filed 2021-05-17 |
| 2020-12-31 | $27.14M 10-K · filed 2022-03-31 |
| 2020-09-30 | $32.56M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $40.77M 10-Q · filed 2021-08-16 |
| 2020-03-31 | $43.33M 10-Q · filed 2021-05-17 |
| 2019-12-31 | $47.48M 10-Q · filed 2021-08-16 |
| 2019-09-30 | $50.34M 10-Q · filed 2020-11-09 |
| 2019-06-30 | $52.04M 10-Q · filed 2020-08-10 |
| 2019-03-31 | $6.97M 10-Q · filed 2020-05-11 |
| 2018-12-31 | $8.25M 10-K · filed 2021-03-31 |
| 2018-09-30 | $10.14M 10-Q · filed 2019-11-12 |
| 2018-06-30 | $10.50M 10-Q · filed 2019-08-09 |
| 2018-03-31 | $3.99M 10-Q · filed 2019-05-10 |
| 2017-12-31 | $3.05M 10-K · filed 2020-03-16 |
| 2017-09-30 | $6.96M 10-Q · filed 2018-11-13 |
| 2017-06-30 | $9.13M 10-Q · filed 2018-08-14 |
| 2017-03-31 | $13.64M 10-Q · filed 2018-05-11 |
| 2016-12-31 | $15.36M 10-K · filed 2019-03-06 |
| 2016-09-30 | $16.06M 10-Q · filed 2017-11-07 |
| 2016-06-30 | $18.00M 10-Q · filed 2017-08-14 |
| 2016-03-31 | $22.36M 10-Q · filed 2017-05-15 |
| 2015-12-31 | $25.85M 10-K · filed 2018-03-29 |
| 2015-09-30 | $21.32M 10-Q · filed 2016-11-08 |
| 2015-06-30 | $26.36M 10-Q · filed 2016-08-09 |
| 2015-03-31 | $29.35M 10-Q · filed 2016-05-10 |
| 2014-12-31 | $29.13M 10-K · filed 2017-03-28 |
| 2014-09-30 | $31.20M 10-Q · filed 2015-11-09 |
| 2014-06-30 | $34.42M 10-Q · filed 2015-08-10 |
| 2014-03-31 | $36.59M 10-Q · filed 2015-05-11 |
| 2013-12-31 | $10.49M 10-K · filed 2016-03-15 |
| 2013-09-30 | $9.71M 10-Q · filed 2014-11-10 |
| 2013-06-30 | $5.10M 10-Q · filed 2014-08-07 |
| 2013-03-31 | $7.02M 10-Q · filed 2014-05-13 |
| 2012-12-31 | $9.36M 10-K · filed 2016-03-15 |
| 2012-09-30 | $11.06M 10-Q · filed 2013-11-12 |
| 2012-06-30 | $13.13M 10-Q · filed 2013-08-14 |
| 2012-03-31 | $15.31M 10-Q · filed 2013-05-10 |
| 2011-12-31 | $6.40M 10-K · filed 2015-03-18 |
| 2011-09-30 | $7.94M 10-Q · filed 2012-11-09 |
| 2011-06-30 | $7.98M 10-Q · filed 2012-08-10 |
| 2011-03-31 | $6.95M 10-Q · filed 2012-05-11 |
| 2010-12-31 | $5.89M 10-K · filed 2013-03-29 |
| 2010-09-30 | $2.81M 10-Q · filed 2011-11-10 |
| 2010-06-30 | $2.86M 10-Q · filed 2011-08-12 |
| 2009-12-31 | $251.00K 10-K · filed 2012-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |